Bolt Biotherapeutics (BOLT)
(Delayed Data from NSDQ)
$1.11 USD
-0.05 (-4.31%)
Updated Apr 26, 2024 03:58 PM ET
After-Market: $1.16 +0.05 (4.50%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
BOLT 1.11 -0.05(-4.31%)
Will BOLT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BOLT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BOLT
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimates
BOLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates
Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy?
Other News for BOLT
Bolt Metals Completes $231K Private Placement
12 Health Care Stocks Moving In Wednesday's After-Market Session
Bolt Biotherapeutics: A Strong Buy on Clinical Progress and Financial Stability
Bolt Biotherapeutics’ Promising Trajectory in Immuno-Oncology: A Strong Buy Recommendation
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Intuitive Surgical (ISRG) and Bolt Biotherapeutics (BOLT)